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Attached is the revised manuscript detailing two families with recessive variants in 
MAN1B1 known to cause a form of CDG-type II. We have expanded the phenotype 
on this rare form of congenital disorder of glycosylation. I hope you are able to 
































































Title: MAN1B1 causing a congenital disorder of glycosylation with a distinct phenotype 
Journal: European Journal of Medical Genetics
Professor Verloes
Editor-in-Chief
European Journal of Medical Genetics
Dear Professor Verloes,
Thank you for considering my manuscript submitted to European Journal of Medical 
Genetics. Please see attached an in-depth revision of the work which is much more concise as 
suggested by the reviewers. I hope this revision meets your approval and you are able to 
consider our work favourably. 
Your’s sincerely,
Meena Balasubramanian
Response to comments from the editors and reviewers:
Response to Edi  comment: declaration to a public database appears missing
Dissemination of the information about published genetic and genomic variants is important. 
As requested in the Guidelines for Authors, at this stage, you have to submit new and rarely 
(less than 5 times) reported DNA variants or CNV mentioned in this article to a public 
database such as ClinVar (http://www.ncbi.nlm.nih.gov/clinvar) or to any other suitable 
public reference database (LOVD, DECIPHER…) before your publication could be 
definitively accepted. Please mention the database and quote accession number(s) in the 
manuscript, in the result section.
Response: Apologies, this has now been added.
-Response to Revi
This manuscript reports on three novel MAN1B1-CDG patients with three novel variants. 
The language needs attention. The text should be made more concise and avoid redundancy 
and self-evident statements. I propose to summarize the reported and present patients in a 
table, so that the discussion can be shortened by referring to this table.
Response: Thank you, we have taken your well thought out suggestions on board and made 
the manuscript concise as suggested below.
The following are corrections, and suggestions for improvement.





























































ABSTRACT: L 47-57: are a group of genetic diseases due to .....It comprises a high ....... and 
a wide range of clinical phenotypes (drop the last sentence; is self-evident)
                 L 62-64: two families each with two siblings with ID
                 L 69-72: included isoelectrofocusing (IEF) of serum transferrin.
                 L 74-77: Results: The four patients were found to have three novel variants in 
MAN1B1 Inherited from their parents. Serum transferrin IEF showed a type 2 pattern.
                 L 79-90: Discussion: The present patients showed the phenotype previously 
reported in MAN1B1-CDG: ID, a characteristic facial dysmorphism, hypotonia, truncal 
obesity, and, in some,       
                              behavioural problems.
                 L 92-101: Conclusion: In unexplained ID, serum transferrin should be included in 
the first-line screening.
INTRODUCTION: L 111-114: lipids. There are over 100 known CDG.
                         L 121-130: to be dropped.
                         L 130-136: CDG due to an N-glycosylation defect are divided into CDG-I 
(glycan assembly defects in cytosol and ER) and CDG-II (glycan remodelling defects in 
Golgi).
                         L 136-147: to be dropped.
                         L 149-158: recessive disorder characterized by variable 
intellectual/developmental disability, a characteristic facial dysmorphism, truncal obesity and 
hypotonia. The facial 
                                         dysmorphism comprises prominent
                         L 164-173: have been reported    . Serum transferrin IEF shows a type 2 
pattern.
CLINICAL REPORT: L 186: aged 8 years, first
                            L 188-190: 'There are .... Well' is not relevant.
                            L 192-197: At the age of 6 months he was noted to be hypotonic and 
showed a delayed development. He sat at 14 months
                            L 207-211: (Figure 1a). Weight was consistently ....., height between the 
50th and 75th centiles and head
                            L 218: Brain MRI at 3.5 years




























































                            L 231: He was able to speak in
                            L 241-253: There was marked truncal obesity although he had a normal 
........ Behaviour. He had a similar facial appearance as before (...). Weight was 60.6 ..... 
centile),  ....132 
                                             cm ...circumference 54 cm. Transferrin IEF, following ..., showed 
a type 2 pattern.
                            L 257-261: He showed delayed development with cruising ..... age, and 
walking at 3 years
                            L 272-278: Weight was 13.9 kg .... centile), height 89 cm .... and ..... 54 cm 
....of age. Brain MRI at 2 years
                           L 285: At 6 years of age, he was ... school; he
                           L 291: by the family
                           L 298: but able to walk
                           L 302: (Fig. 2c). Weight was
                           L 307: showed a type 2 pattern.
                           L 318-322: noted. She walked at 19 months of age and her first ....... 18 
months
                           L 336: back. Weight was .... (between 91st and 98th centiles) ... 126 cm  ... 
centiles ..... cm
                           L 345-360: support. Weight was ..... cm ..... showed a type 2 pattern.
                           L 362: is the younger ... of patient 3... At 6 years, she was
RESULTS: L 402, 403: identified in patient 1 a
               L 407-409: reported before. In silico
               L 416, 417: was found .... variant as his brother. These
DISCUSSION: L 438-442: ( ....) has 13 coding exons and encodes a Golgi mannosidase. This 
enzyme is involved in the N-glycan remodeling.
                    L 445-495: I suggest to remove this part because it is not really relevant for this 
case report.
FIGURE LEGENDS: L 804, 811 and 818: patient




























































 Response: Thank you, I have incorporated all the above changes in keeping with the style of 
written text.   
-Response to Revi
The authors presented two families with MAN1B1&#xff0d;CDG.　MAN1B1-CDG is very 
rare. But undiagnosed patients with MAN1B1-CDG may exist. Clinical report is well written. 
Figures for molecular studies are not enough.
1. The authors should show the results of transferrin glycoforms by IEF.
2. 　The authors should show the family trees.
3. 　All reported patients with MAN1B1-CDG should be summarized in a Table.
4.  Screening for CDG should include O-linked type abnormalities.
Minor points
In page 5, golgi should be Golgi.
Line 519, then should be there.
Response: Thank you for your excellent suggestions which have now been incorporated.
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ABSTRACT
Background: Congenital disorders of glycosylation (CDG) are a group of rare metabolic 
diseases due to impaired lipid and protein glycosylation. It comprises a characteristic high 






























































Objective(s): To identify the underlying diagnosis in two families each with two siblings with 
variable level of ID through trio whole exome sequencing.
Methods:  Both the families were recruited to the Deciphering Developmental Disorders 
(DDD) study to identify the aetiology for their ID. Further work-up included isoelectric 
focusing (IEF) of serum transferrin done to add evidence to the molecular diagnosis.
Results: The four patients were found to have three novel variants in MAN1B1 inherited from 
their healthy parents. Serum transferrin IEF showed a type 2 pattern.
Discussion: MAN1B1 variants were initially described in association with non-syndromic ID; 
subsequent literature suggested that variants in MAN1B1 resulted in a CDG-type II syndrome. 
However, there remains a paucity of literature on detailed clinical phenotyping and it still 
remains a rare form of CDG. The present patients showed the phenotype previously reported 
in MAN1B1-CDG: a characteristic facial dysmorphism, hypotonia, truncal obesity and in 
some, behavioural problems. 
Conclusions: In unexplained ID, serum transferrin should be included in the first-line 
screening. With advances in genomic medicine, it is important to diagnose CDG as this has 
implications for management and recurrence risk counselling.
INTRODUCTION
Congenital disorders of glycosylation (CDG) are a rapidly growing group of inborn errors of 
metabolism with abnormal glycosylation of proteins and lipids. There are over 100 known 
CDG. CDG due to an N-glycosylation defect are divided into CDG-I (glycan assembly 
defects in cytosol and endoplasmic reticulum (ER)) and CDG-II (glycan remodelling defects 






























































heterogeneous clinical presentation with lack of specific clinical clues to suggest an 
underlying diagnosis. This is especially true for MAN1B1-CDG(1).
MAN1B1-CDG is an autosomal recessive disorder characterized by variable 
intellectual/developmental disability, a characteristic facial dysmorphism, truncal obesity and 
hypotonia. The facial dysmorphism comprises prominent eyebrows with lateral thinning, 
downward-slanting palpebral fissures, bulbous tip of the nose, large ears and thin upper lip. 
Behavioural problems including overeating, verbal and physical aggression have also been 
reported in some cases. Serum transferrin IEF shows a type 2 pattern (2).
CLINICAL REPORT
Patient 1: Patient 1 is the older sibling in Family 1 aged 8-years, first child of healthy, non-
consanguineous White European parents with no significant family history (Figure 1a). He 
was born following a normal pregnancy at term with a birthweight of 3.37 kilograms (25th 
centile). At the age of 6 months, he was noted to be hypotonic and delayed with his 
development. He sat at 14-months, crawled at 19-months and started walking at over 2 years 
but remained unsteady on his feet with a wide-based gait. He had no speech and 
communicated using Makaton. He was reported to have occasional night tremors but no overt 
seizures. He was reviewed in the Genetics clinic from 2-years and noted to be dysmorphic 
with anterior hair whorl, frontal bossing, hypertelorism, downward-slanting palpebral fissures 
and a mild pectus carinatum (Figure 1b). Weight was consistently above the 91st centile, 
height between the 50th-75th centiles with head circumference on 50th centile. Investigations 
at the time included normal 60K arrayCGH, chromosome breakage studies and metabolic 
work-up (including plasma and urinary amino acids and organic acids, CK, serum lactate, 






























































normal (Figure 1c) and MR spectroscopy was essentially normal. He was subsequently 
enrolled to the DDD study and saliva samples taken for trio WES (Decipher ID: 272692).
At recent review aged 8-years, he was in a mainstream school with additional support, was 
able to read and write. He remained unsteady on his feet with supportive footwear. He was 
able to speak in short sentences. He had a happy, friendly personality and there were no 
behavioural concerns. He had been toilet-trained since 6-years of age. There was marked 
central obesity although he had normal appetite and no food-seeking behaviour. He had a 
similar facial appearance to before (Figure 1d-e); weight~60.6 kilograms (75th-91st centile); 
height~132 cms (75th centile) and head circumference of 54 cms (50th centile). Transferrin 
IEF, following identification of MAN1B1 variants, showed a type 2 pattern.
 Patient 2 is the younger sibling of Patient 1 (Family 1) aged 6-years. He was born 
following a normal pregnancy at term with a birth weight of 4.22 kilograms (91st centile). He 
was well immediately after birth but again was noted to be delayed with his development 
with cruising around furniture at 14-months, walking at 3-years but had no speech and unlike 
his brother, was not communicating by sign language. He was also noted to be hypotonic and 
wears glasses for hypermetropia. He was noted to be aggressive on occasions and had a 
quieter personality than his older sibling. He was initially reviewed in the Genetics clinic at 
2.5-years of age and noted to be dysmorphic with similar facial appearance to his brother 
(Figure 2a). He also had mild 2-3 toe syndactyly, frontal bossing; weight~13.9 kilograms 
(50th-75th centile); height~89 cms (25th-50th centile) and head circumference~54 cms (98th 
centile) at 2.5-years of age. MRI-brain at 2-years of age identified bilateral periventricular 
heterotopia with overlying cortical dysplasia which was thought to account for his more 






























































At recent review aged 6-years, he was in a special needs school, he still remained in nappies. 
His sleep and appetite were reported to be normal. He wore glasses and a back brace for 
correction of scoliosis. He had no speech and was noted by the family to have occasional 
aggressive outbursts. He was in a wheelchair for long distances, but able to walk 
independently for short distances. There was less evidence of truncal obesity. On 
examination, he was noted to have similar facial dysmorphism as his brother (Figure 2c); 
weight~28.5 kilograms (98th centile); height~119 cms (75th centile) and head circumference 
of 57 cms (98th centile). Transferrin IEF, following identification of MAN1B1 variants, 
showed a type 2 pattern.
 This patient is the older sibling in Family 2, aged 10-years and is the first child of 
healthy, non-consanguineous White European parents with no significant family history 
(Figure 3a). There were no concerns in the pregnancy and she was born at term+2 weeks 
gestation with a birth weight of 4.30 kilograms (98th centile) by forceps delivery. She was in 
a good condition immediately after birth and there were no feeding problems noted. She 
walked at 19-months of age and her first words were at 18-months of age. She was in 
mainstream school with additional 1:1 support.  She was also noted to have occasional 
outburst of aggressive behaviour.
This patient was initially reviewed in the Genetics clinic aged 7-years following a referral by 
the Community paediatric team in view of her developmental impairment. On examination, 
she was noted to be dysmorphic with downward-slanting palpebral fissures, hypertelorism 
with epicanthic folds, full lips (Figure 3b) and a café-au-lait patch on her right lower back; 
weight~31.5 kilograms (91st-98th centiles); height~126 cms (75th-91st centiles) and head 
circumference~54.3 cms (75th centile). She was recruited to the DDD study and saliva 






























































At recent review aged 10-years, she was noted to be in a mainstream school with support. She 
was noted to have similar facial dysmorphism as before (Figure 3c); weight~48.2 kilograms 
(91st-98th centiles) and height~140.6 cms (75th centile). Transferrin IEF, following 
identification of MAN1B1 variants, showed a type 2 pattern.
 This patient in the younger sibling of Patient 3. Aged 6-years, she was referred to 
Genetics following identification of a MAN1B1-CDG in the older sibling. There were initial 
concerns in the first year of life regarding dairy intolerance but this settled. She was 
subsequently referred to Ophthalmology for hypermetropia needing glasses. She was noted to 
have non-specific mild global developmental delay and referred to the Genetics clinic 
following the diagnosis in her older sibling.
MATERIALS AND METHODS
Both families 1 and 2 were recruited to the Deciphering Developmental Disorders (DDD) 
study. Trio-based exome sequencing was performed on the affected individual and their 
parents, as previously described(3).  Each affected individual also had a high-resolution 
analysis for copy number abnormalities using array-based comparative genomic 
hybridization (aCGH).  Putative de novo mutations were identified from exome data using 
DeNovoGear software(4) and were validated using targeted Sanger sequencing.
RESULTS
Genetic analysis: 
Trio WES through DDD study identified in Patient 1 a homozygous c.1311del,p.Leu438fs 






























































This variant has not been reported before; in silico analysis supports its likely pathogenicity 
confirming the diagnosis of MAN1B1-CDG. Patient 2 was found to carry the same 
homozygous variants as seen in his brother. These variants were biparentally inherited. This 
result was confirmed by Sanger sequencing. 
In Family 2, trio WES in Patient 3 identified compound heterozygous MAN1B1 variants: a 
likely pathogenic c.761_764del,p.Ile254Thrfs*20 frameshift variant and a missense 
c.1000C>T,p.Arg334Cys in MAN1B1 (NM_016219.4- HGVS nomenclature) which was 
biparentally inherited (Figure 3d and e).  In silico analysis supports its likely pathogenicity 
confirming the diagnosis of MAN1B1-CDG. Both the variants are publicly accessible via the 
Decipher website (https://decipher.sanger.ac.uk) using their Decipher ID numbers.
USSION
MAN1B1 (OMIM 604346) which is situated on chromosome 9q34.3, has 13 coding exons 
and encodes a Golgi mannosidase. These enzymes are involved in N-glycan remodelling.  
These enzymes also contribute to the timing and disposal of misfolded glycoproteins through 
the ER associated degradation (ERAD) pathway. ERManI cleaves the terminal mannose from 
the middle branch of Man9GlcNAc2, producing a Man8GlcNAc2 isomer B. This is believed 
to play a critical role in glycoprotein quality control by targeting terminally misfolded 
proteins in ERAD. MAN1B1 was initially predicted to act as an ER-resident protein(5) but 
recent studies have shown that MAN1B1 localises to the Golgi apparatus in mammalian 
cells(6), further reinforcing the fact that quality control is not confined to ER alone but extends 
through the secretory pathway(1). This provides further evidence that MAN1B1 operates as a 
check-point within the Golgi apparatus recycling misfolded proteins that escaped ERAD back 






























































proteins(7). It is also said to act as a lectin retrieving these proteins back to the ER prior to 
degradation(1).
The likely explanation for MANB1 deficiency resulting in a multi-system disorder is due to 
the fact that there is defective quality control as a result of MAN1B1 genetic defects, resulting 
in defective check-point unable to minimise the level and toxicity of misfolded proteins 
within the cell. Interestingly, compared to most CDG phenotypes, MAN1B1-CDG 
considering how important MAN1B1 activity is within the cell, only presents with a milder 
phenotype. This supports the hypothesis that there may be more check-points within the ER-
Golgi machinery. Further work on the secretory pathway and its regulation in various body 
systems will provide further insight into the phenotypic contribution of specific forms of 
CDG.
Recessive variants in MAN1B1 were first identified in non-syndromic mental retardation-15 
(MRT15; OMIM 614202) in four consanguineous families by Rafiq et al., 2011(8). By 
undertaking WES and homozygosity mapping in these families with several affected siblings 
in one generation, they were able to identify several candidate genes narrowing it down to 
variants in MAN1B1 as being causal8. The authors characterised the phenotype as being 
consistent with non-syndromic AR ID except in one family (MR43) with a nonsense variant 
where clear dysmorphism was identified, no photographs of this family were however 
published. Description of the facial features is however very similar to the facial phenotype 
we describe in our families. The authors concluded that ERAD is a new disease associated 
pathway and disruption of other ERAD pathway candidates may result in a similar clinical 
phenotype.
Since then, there have been very few cases of MANB1-CDG reported so far and matchmaker 






























































matches suggesting this remains a rare, potentially undiagnosed form of CDG. This is likely 
because of the varying presentation and what is initially thought to be a non-specific 
presentation as evidenced by our families. However, by including transferrin IEF in initial 
screening of global developmental delay, along with other routine investigations such as 
urinary organic acids, plasma amino acids will help pick this up early. Screening for CDG 
should also include O-linked type abnormalities. However, interestingly, the CDG-type II 
pattern seen may also indicate sample degradation requiring a repeat sample for confirmation 
which in this cohort may not always be possible. With further genomic advances (and 
resultant cost-benefit), use of first-line WES/ WGS in clinical practice for diagnostic work-up 
of children with developmental delay should hopefully address this issue. It is important, 
however, to ensure that WES/ targeted gene panels thus generated for developmental delay 
include genes associated with CDG.
Table 1 summarises all the patients reported so far with MAN1B1-CDG in comparison to our 
cohort. Rymen et al., 2013 reported seven patients with recessive variants in MAN1B1 from 
their cohort of unsolved CDG-type II and were able to provide further functional evidence of 
MAN1B1 role in protein quality at the Golgi apparatus(1). All patients had hypotonia, variable 
degree of ID, truncal obesity but with normal MRI-brain in all but one patient who also 
presented with epilepsy. Behavioural problems do not appear to be a major component of the 
phenotype unlike some other CDG identified so far.
Van Scherpenzeel et al., 2014 reported twelve patients with MAN1B1 recessive variants from 
their cohort of molecularly undiagnosed CDG-type II patients(9). Patients in this study 
showed a predominant neurological phenotype with moderate ID. They were also noted to 
have macrocephaly, truncal obesity, early hypotonia and characteristic facial dysmorphism 
including an oval face, bulbous nasal tip with thin upper lip. However, many of the patients 






























































distribution and cutis laxa. They did have a variable phenotype including intra-familial 
variability as is apparent in the families we report here.
Since these publications of two large cohort of patients with MAN1B1-CDG, there have only 
been couple more reports of this in literature(10,11). Hoffjan et al., 2014 reported a Turkish 
consanguineous family with three affected siblings and recessive variants in MAN1B1 with a 
similar phenotype as previously reported patients(10). Gupta et al., 2016 reported two patients 
with digenic inheritance: homozygous variants in two recessive genes, SEC23A which is 
associated with Cranio-lenticulo-sutural dysplasia (CLSD) and MAN1B1(11). The authors 
suggest a composite phenotype with variants in both these genes contributing to their clinical 
presentation.
So far, there seems to be a combination of missense, nonsense, deletion and splicing variants 
reported and there is no clear emerging genotype-phenotype correlation. However, the 
number of reported cases is still small, so with further cases being reported this may provide 
us with further clues to clarify phenotypic variability. Although there is no treatment or 
curative therapy for MAN1B1-CDG and management is purely symptomatic, it is likely that 
with advances in precision medicine, identifying the underlying genetic aetiology early in 
patients with CDG-type II may have an impact on outcomes.
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FIGURE LEGENDS
Figure 1a-e: Family pedigree and photographs of patient 1 at 3 and 8 years of age 
demonstrating frontal bossing, oval face, down-slanted palpebral fissures, thin upper lip; 
MRI-brain demonstrating nonspecific right frontal high signal but otherwise essentially 
normal. 
Figure 1f: Trio WES identified in Patient 1 a homozygous c.1311del,p.Leu438fs likely 






























































Figure 2a-c: Photographs of patient 1 at 3 and 6 years of age demonstrating similar facial 
dysmorphism to his older sibling; MRI-brain demonstrating bilateral temporal heterotopia.
Figure 3a-c: Pedigree and photographs of patient 3 at 7-years and 10-years of age 
demonstrating facial dysmorphism as previously described.
Figure 3d-e: Trio WES in Patient 3 identified compound heterozygous MAN1B1 variants: a 
likely pathogenic c.761_764del,p.Ile254Thrfs*20 frameshift variant and a missense 
c.1000C>T,p.Arg334Cys in MAN1B1 (NM_016219.4- HGVS nomenclature) which was 






























































al features reported in patients with MAN1B1-CDG in comparison to our cohort

















Facial dysmorphism  4/4 10/10 7/7 7/12 3/3 2/2 38/38 (100%)
Seizures 0/4 2/12 1/7 3/12 0/3 ?2/2 8/40 (20%)
Hypotonia 4/4 10/12 7/7 8/12 3/3 2/2 34/40(85%)
Truncal obesity 3/4 2/12 7/7 8/12 3/3 2/2 25/40 (62%)
Delayed development 4/4 12/12 7/7 12/12 3/3 2/2 40/40 (100%)
Intellectual Disability 4/4 12/12 7/7 12/12 3/3 2/2 40/40 (100%)
Behavioural concerns 2/4 2/12 2/7 3/12 0/3 0/2 9/40 (22%)
Abnormal MRI-brain 1/4 1/1 2/7 2/10 1/1 1/2 8/25 (32%)
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